• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical investigation >Presentations at EADV 2012 show ustekinumab improves quality of life in patients with plaque psoriasis
【24h】

Presentations at EADV 2012 show ustekinumab improves quality of life in patients with plaque psoriasis

机译：在EADV 2012上的演讲显示，ustekinumab改善了斑块状牛皮癣患者的生活质量

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Results from the TRANSIT study presented at EADV 2012 showed that ustekinumab, which targets interleukin-12 and interleukin-23, significantly improved quality-of-life outcomes and was well tolerated in patients transitioning from methotrexate therapy. In addition, a presentation on the PHOENIX 2 study, involving 1230 patients with moderate-to-severe plaque psoriasis who received up to 5 years treatment with ustekinumab, showed long-term maintenance of high levels of clinical responses when being treated with ustekinumab. Furthermore, preliminary findings from the PSOLAR study revealed that, to date, no new malignancy, infection or major adverse cardiovascular events have been identified in patients undergoing ustekinumab therapy.
机译：在EADV 2012上发表的TRANSIT研究结果表明，针对白介素12和白介素23的乌斯他单抗显着改善了生活质量，并且在从甲氨蝶呤治疗过渡的患者中得到了很好的耐受。此外，有关PHOENIX 2研究的报告涉及1230例接受优特克单抗治疗长达5年的中度至重度斑块状牛皮癣患者，显示了用优特克单抗治疗后可长期维持高水平的临床反应。此外，PSOLAR研究的初步发现表明，迄今为止，在接受ustekinumab治疗的患者中尚未发现新的恶性肿瘤，感染或重大不良心血管事件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号